Q3 reported results include 19 percent sales growth and EPS of $.85 Q3 pro forma adjusted results include 13 percent sales growth and EPS of
$.91 Full-year pro forma adjusted EPS guidance updated to $3.50 - $3.55, or
$2.76 - $2.81 reported
INDIANAPOLIS, Oct. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the third quarter of 2007 and raised its full-year pro forma adjusted earnings per share guidance. The company now expects full-year pro forma adjusted earnings per share to be in the range of $3.50 to $3.55 per share, or $2.76 to $2.81 per share on a reported basis.
Throughout this release, financial results are presented on both a reported and a pro forma adjusted basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all sales and expenses recognized by the company during the period. Pro forma adjusted results exclude items described in the reconciliation tables below and also assume the ICOS acquisition was completed January 1, 2006. The pro forma adjusted results are presented in order to provide additional insights into the underlying trends in the business. Financial guidance is also provided on both a reported and a pro forma adjusted basis.
Third-Quarter Highlights - Reported Results
-- Sales increased 19 percent, to $4.587 billion.
-- Products launched this decade - Alimta(R), Byetta(R), Cialis(R),
Cymbalta(R), Forteo(R), Strattera(R), Symbyax(R), Xigris(R) and
Yentreve(R) - collectively grew 56 percent, to $1.498 billion, and
accounted for 33 percent of tota
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved